Tigecycline Activity Tested against Carbapenem-Resistant Enterobacteriaceae from European Hospitals: Results from the SENTRY Program (2010-2013)

Results: Overall, 1.9% (268/14,286) of Enterobacteriaceae strains were CRE. The highest CRE frequency was observed in Poland (16.1%; 65/405), followed by Italy (7.4%, 129/1,743), Greece (7.1%; 43/605) and Romania (5.0%; 8/157). No CRE (0.0%) was noted in Ireland (1,192 strains tested), Portugal (529), Slovakia (113), Slovenia (237), Sweden (418) and the United Kingdom (1,180). CRE rates were 0.2-2.6% in the remaining nations included in the investigation. Poland, Italy and Greece accounted for 88.4% of CRE strains. The most common CRE species were Klebsiella pneumoniae (237; 88.4%) and Enterobacter cloacae (18; 6.7%). CRE were isolated mainly from bacteremia (39.6%), pneumonia (24.3%), cSSTI (13.4%), urinary tract infections (12.7%) and cIAI (5.2%). Tigecycline (98.3% susceptible), imipenem (98.2%) and meropenem (98.1%) were the most active agents tested against Enterobacteriaceae overall; whereas only tigecycline exhibited good in vitro activity against CRE (MIC 50/90 , 0.5/2 mg/L; 88.4% susceptible). Among carbapenem-resistant K. pneumoniae, 91.1% were susceptible to tigecycline (MIC 50/90 ,